US FDA extends comment deadline for guidance on companion diagnostics
This article was originally published in Clinica
Executive Summary
The US FDA has extended until 12 October the deadline by which stakeholders can comment on a draft guidance that explains the agency's policy on reviewing companion diagnostic tests used to tailor drug therapies to patients. The original comment period was to end on 12 September.